AZD-5335 is under clinical development by AstraZeneca and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition success rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback